EFFECT OF SIMVASTATIN ON SERUM CTRP5, MMP-2, MMP-9 AND TIMP-1 IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Zhen Hu*, #, Xingyu Jiang*, Jiequn Li**

*Department of Respiratory Medicine, The Second People's Hospital of Jingdezhen, Jingdezhen, PR China - **Department of Laboratory, The Second People's Hospital of Jingdezhen, Jingdezhen, PR China

Objective: To investigate the effects of simvastatin on serum CTRP5, MMP-2, MMP-9 and TIMP-1 in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods: Ninety patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to our hospital from October 2017 to May 2018 were enrolled. The patients were divided into a control group and an observation group according to different treatment methods, for a total of 45 cases each. For example, patients in the control group were treated with conventional AECOPD regimen after admission, while patients in the observation group were treated with simvastatin tablets on the basis of the control group, 20 mg/d for four weeks. The clinical efficacy and adverse reactions of the two groups were compared, including the level changes of complement C1q tumour necrosis factor-related protein (CTRP5), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase (MMP-9), and matrix metalloproteinase tissue inhibitor of the two groups. The changes of pulmonary function indicators [forced respiration volume at the first second (FEV1), forced lung capacity (FVC), the percentage of FEV1/FVC and FEV1 in the estimated value (fev1%)] were compared. 

Results: The total effective rate of the observation group was 95.56%, which was significantly higher than that of the control group (77.78%) (P<0.05). The levels of CTRP5, MMP-2, MMP-9 and TIMP-1 in the two groups were significantly lower than those before treatment (P<0.05). Furthermore, the levels of CTRP5, MMP-2, MMP-9 and TIMP-1 were significantly lower in the observation group than the control group (P<0.05). After treatment, the lung function indexes FVC, FEV1, and FVC/FEV1 were significantly higher in the two groups than before treatment (P<0.05). The lung function indexes FVC, FEV1, FVC/FEV1 in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group 8.89% and the control group 11.11% (P>0.05). 

Conclusion: Simvastatin is effective in the treatment of AECOPD patients with mild adverse reactions and high safety. It can effectively improve lung function indexes and reduce CTRP5, MMP-2, MMP-9 and TIMP-1 levels in patients with AECOPD.